First Trust NYSE Arca Biotech Index Fd

Veracyte Inc. CEO reports common stock disposition

Biogen CEO Purchases Company Stock

Natera Inc. CEO Disposes of Common Stock

Natera's Clinical Diagnostics President Reports Sale of Ordinary Shares

Biogen advances immunology pipeline, felzartamab shows promise in multiple diseases

Sanofi and Regeneron Obtain EU Approval for Dupixent to Treat Chronic Urticaria

Natera Inc. showcases new data for Signatera™ at ASH annual meeting

Biogen and Eisai Showcase LEQEMBI's Pharmacological Effect on Alzheimer's Patients

Sorrento Therapeutics Outlines Jakafi Follow-Up Growth Strategy

Sette Healthcare Collaborates with Winnie Harlow for Vitiligo Awareness Campaign

Natera to Present Signatera Detection Data at San Antonio Breast Cancer Symposium

Stoke Therapeutics and Biogen to Present New Clinical Data on Zorevunersen at AES Annual Meeting

New York State Common Retirement Fund Reduces Holdings in Regeneron Pharmaceuticals

Regeneron and Tessera Collaborate on Gene Editing Therapy

Loomis Sayles Reduces Stake in Natera, Stock Rises

Intech Investment Management LLC Reduces Holdings in Natera Inc.

Abbott Announces $21 Billion Acquisition of Alere to Enhance Diagnostic Business

Incyte Announces Significant Positive Results from Long-term Tafasitamab Study

Coldstream Capital Management Inc. Increases Stake in Illumina

Biogen Collaborates with Dayra on Oral Macrocyclic Peptides for Immune Diseases

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

SMX Security Matters

Polyrizon

Picard Medical

Synchronoss Tech

PharmaCyte Biotech

Q/C Tech

Rich Sparkle

Hoyne Bancorp

Tradr 2X Long ASTS Daily ETF

VCYT

Officer Febbo Phillip of Veracyte Inc surrendered 2,955 shares back to the company to cover option exercise costs and tax liabilities, as disclosed in a Form 4 filed with the SEC on December 4, 2025. The transaction was valued at $136,403, with shares priced at $46.16. Febbo's ending holdings are 89,486 shares directly.

Reuters

Veracyte

Officer Febbo Surrenders 2,955 Of Veracyte Inc [VCYT]

Veracyte Inc's Vice President, Jonathan Wygant, surrendered 1,325 shares at $46.16 each, valued at $61,162, to cover option exercise costs and/or tax liabilities. His remaining direct holdings are 37,420 shares.

VP Wygant Surrenders 1,325 Of Veracyte Inc [VCYT]

Veracyte Inc's Vice President, Annie McGuire, disclosed a Form 4 filing with the SEC, indicating a surrender of 3,052 shares and a planned sale of 1,422 shares, valued at $67,261, under a prearranged trading plan. The transaction was executed to cover option exercise costs and tax liabilities, leaving McGuire with 78,499 direct holdings.

VP McGuire Sells 1,422 ($67.3K) Of Veracyte Inc [VCYT]

Veracyte Inc's CEO, Marc Stapley, disclosed a stock transaction involving the sale of 7,668 shares for $361,075, as per a Form 4 filed with the SEC. The transaction was part of a prearranged trading plan (10b5-1). Additionally, 7,914 shares were surrendered to cover option exercise costs and tax liabilities. Stapley's direct holdings now total 318,603 shares.

CEO Stapley Sells 7,668 ($361.1K) Of Veracyte Inc [VCYT]

Officer John Leite of Veracyte Inc filed a Form 4 with the SEC, disclosing a surrender of 2,900 shares and a planned sale of 1,278 shares under a 10b5-1 trading plan. The transactions were executed to cover option exercise costs and tax liabilities, with ending holdings of 82,113 shares.

Officer Leite Sells 1,278 ($60.7K) Of Veracyte Inc [VCYT]

Rebecca Chambers, CFO of Veracyte Inc, disclosed a sale of 13,278 shares worth $621,955, executed under a prearranged trading plan. Additionally, 3,384 shares were surrendered to cover option exercise costs and tax liabilities. Her ending holdings are 109,496 shares. The transaction was filed with the SEC on December 4, 2025.

CFO Chambers Sells 13,278 ($622K) Of Veracyte Inc [VCYT]

Veracyte Inc.'s CEO, Marc Stapley, reported the disposal of common shares. The filing is available via EDGAR, the SEC's system. This AI-generated news brief is for informational purposes only and not financial advice. Veracyte Inc. is responsible for the original content.

Veracyte CEO Marc Stapley Reports Disposal of Common Shares

INCY

Incyte Corp. (INCY) shares fell 1.02% to $100.46 on Thursday, despite a mixed trading session where the S&P 500 rose 0.11% and the Dow Jones fell 0.07%. The stock is 8.07% below its 52-week high. Competitors like Alnylam Pharmaceuticals, Bio-Techne, and BioMarin Pharmaceutical also saw declines. Trading volume was below the 50-day average.

Dow Jones

Incyte

Incyte Corp. Stock Outperforms Competitors Despite Losses On The Day

BIIB

Biogen's Alzheimer's treatments, targeting amyloid deposits, have shown a 30% delay in disease progression, unlike Novo Nordisk's semaglutide, which offered no cognitive benefits for early patients.1On December 3, 2025, Biogen CEO Christopher Viehbacher acquired 3,636 shares, increasing his total to 16,443. Some shares were surrendered to cover option costs and taxes.2

TradingView

Biogen

Key facts: Biogen's Alzheimer's drug delays progression by 30%; CEO boosts shares

Biogen and Eisai presented new LEQEMBI data at the CTAD conference, highlighting long-term benefits in Alzheimer's progression and a new subcutaneous formulation. This could enhance Biogen's investment narrative by potentially improving treatment uptake. However, challenges remain with Alzheimer's uptake, reimbursement, and competition. Biogen's collaboration with Dayra Therapeutics aims to diversify its pipeline. Despite LEQEMBI's promising data, investors should consider pricing and reimbursement pressures on specialty drugs. Biogen's projected revenue is $9.4 billion by 2028, with varied community valuations reflecting differing expectations.

Simplywall

Should New LEQEMBI Data and Subcutaneous Option Shift the Risk Profile for Biogen (BIIB) Investors?

Eisai Co., Ltd. and Biogen Inc. presented new data at the 18th CTAD Conference on lecanemab, a monoclonal antibody for Alzheimer's treatment. Findings suggest early and long-term use of lecanemab slows disease progression, with significant time savings in progression from MCI to mild and moderate AD. The subcutaneous formulation shows similar efficacy and safety to intravenous dosing. Eisai leads global development and regulatory submissions, co-commercializing with Biogen.

marketscreener

Eisai Co., Ltd. and Biogen Inc. Present New Data

NTRA

Natera's CEO and President, Steven Leonard Chapman, and President of Clinical Diagnostics, Solomon Moshkevich, both sold shares of the company's common stock on December 1, 2025. Chapman sold 4,400 shares for $1,047,501, reducing his ownership to 140,416 shares. Moshkevich sold 3,000 shares for $714,458, reducing his ownership to 109,061 shares. Both transactions were executed under Rule 10b5-1 trading plans.

Natera

Natera Executives Engage in Stock Sales

Moshkevich Solomon Officer of Natera Inc [NTRA] filed a Form 4 on December 3, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/1/25TransactionPlanned Sale(1) Shares3,000Price$238.15Value$714,459Ending Holdings: 109,061 - Direct(1) Executed pursuant to a prearranged trading plan (10b5-1).For a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

Officer Moshkevich Sells 3,000 ($714.5K) Of Natera Inc [NTRA]

Solomon Moshkevich, President of Clinical Diagnostics at Natera Inc., reported the sale of common shares of the company. The full filing is available via EDGAR, the U.S. SEC's system.

Natera President of Clinical Diagnostics Solomon Moshkevich Reports Sale of Common Shares

Natera Inc.'s CEO and President, Steven Leonard Chapman, has reported the disposal of common shares of the company. The details are available in the filing on EDGAR, the SEC's system. This announcement is informational and not financial advice.